EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains

Tsuyoshi Uehara iD, Cassandra L Chatwin, Brittany Miller, Mitchell Edwards, Annie Stevenson, Jenna Colombo, David A Six iD, Denis M Daigle iD, Greg Moeck iD, Steven A Boyd iD, Daniel C Pevear

Antimicrobial Agents and Chemotherapy · 07.05.2025 · 69 (5)

DOI: 10.1128/aac.01699-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.05.2025. Verfasst von Tsuyoshi Uehara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Venatorx Pharmaceuticals Inc, Malvern, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cefepime, beta-Lactamases, Escherichia coli, Anti-Bacterial Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Advanced Research and Development Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefepime-taniborbactam is a β-lactam/β-lactamase inhibitor combination in clinical development for the treatment of Enterobacterales and Pseudomonas infections, including carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa . Taniborbactam is a novel cyclic boronate with direct inhibitory activity against clinically relevant Ambler class A, B, C, and D β-lactamases. To further characterize the spectrum of β-lactamase coverage by cefepime-taniborbactam, we constructed 190 isogenic strains of Escherichia coli that constitutively expressed a different β-lactamase. Synthetic codon-optimized genes encoding the mature periplasmic protein linked to the TEM-1 signal sequence were used for optimized expression and periplasmic localization of the β-lactamase. The repertoire of β-lactamases consisted of 50 Ambler class A, 34 class B (metallo), 48 class C, and 58 class D enzymes known to mediate β-lactam resistance in the clinical isolates of Enterobacterales and P. aeruginosa . Overall, in the 190 isogenic strains, the MIC 50 /MIC 90 values were 8/128 µg/mL for cefepime and >128/>128 µg/mL for ceftazidime. Cefepime-taniborbactam (MIC 50 /MIC 90 of 0.25/8 µg/mL) showed greater activity than ceftazidime-avibactam (MIC 50 /MIC 90 of 4/>128 µg/mL) and similar activity to aztreonam-avibactam (MIC 50 /MIC 90 of 0.5/4 µg/mL). Cefepime-taniborbactam inhibited strains overproducing metallo-β-lactamases, including clinically important NDM and VIM enzymes, whereas ceftazidime-avibactam showed no coverage. Among the 129 β-lactamase-overproducing strains with increased cefepime MIC ≥16-fold relative to the control strain, taniborbactam potentiated cefepime MIC by ≥8-fold for 113 strains overexpressing β-lactamases (42 Ambler class A, 24 B, 23 C, and 24 D). Cefepime-taniborbactam demonstrated broader activity relative to ceftazidime-avibactam and comparable activity with aztreonam-avibactam in the overall coverage of both serine- and metallo-β-lactamases from all four Ambler classes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cefepimebeta-LactamasesEscherichia coliAnti-Bacterial Agentsbeta-Lactamase InhibitorsBorinic AcidsCephalosporinsMicrobial Sensitivity TestsPseudomonas aeruginosaAzabicyclo CompoundsHumansDrug CombinationsCarboxylic Acids

Stichwörter der Autor:innen

aztreonam-avibactamcefepime-taniborbactamceftazidime-avibactaminhibition spectrumβ-lactamases

Substanzen

Cefepimebeta-LactamasesAnti-Bacterial Agentstaniborbactambeta-Lactamase InhibitorsBorinic AcidsCephalosporinsAzabicyclo CompoundsDrug CombinationsCarboxylic Acids

Autor:innen und Institutionen

  • Venatorx Pharmaceuticals Inc, Malvern, Pennsylvania, USA.

ORCID-Profile: Tsuyoshi Uehara, David A Six, Denis M Daigle, Greg Moeck, Steven A Boyd

Förderung

  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Uehara, T., Chatwin, C. L., Miller, B., Edwards, M., Stevenson, A., Colombo, J., Six, D. A., Daigle, D. M., Moeck, G., Boyd, S. A., & Pevear, D. C. (2025). Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains. Antimicrobial Agents and Chemotherapy, 69(5). https://doi.org/10.1128/aac.01699-24

Vancouver

Uehara T, Chatwin CL, Miller B, Edwards M, Stevenson A, Colombo J, et al. Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains. Antimicrobial Agents and Chemotherapy. 2025;69(5). doi:10.1128/aac.01699-24

BibTeX
@article{Uehara2025,
  author = {Uehara, Tsuyoshi and Chatwin, Cassandra L and Miller, Brittany and Edwards, Mitchell and Stevenson, Annie and Colombo, Jenna and Six, David A and Daigle, Denis M and Moeck, Greg and Boyd, Steven A and Pevear, Daniel C},
  title = {Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {5},
  doi = {10.1128/aac.01699-24}
}
Kostenlos starten →